Florfenicol + Terbinafine + Mometasone Furoate

Verify with FDA CVM →

21 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
2
Deaths Reported
950.0%
Death Rate

Active Ingredients

Florfenicol + Terbinafine + Mometasone Furoate

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 21

Most Affected Breeds

Retriever - Labrador 3
Spaniel - Cocker American 2
Shiba Inu 1
Terrier (unspecified) 1
Schnauzer (unspecified) 1
Terrier - Yorkshire 1
Retriever - Golden 1
Bulldog 1
Pit Bull 1
Unknown 1

Most Reported Reactions

Vomiting 7
Decreased urine concentration 2
Death 2
Lack of efficacy - NOS 2
Ear infection NOS 2
Lethargy (see also Central nervous system depression in Neurological) 2
Diarrhoea 2
Vestibular disorder NOS 1
Head tilt - ear disorder 1
Tremor 1
Hind limb ataxia 1
Proprioception deficit 1

Outcome Breakdown

Recovered/Normal
7 (33.3%)
Outcome Unknown
7 (33.3%)
Ongoing
5 (23.8%)
Died
2 (9.5%)

Data Summary

Metric Value
Total adverse event reports 21
Reports involving death 2
Case-fatality rate (reported events) 950.0%
Distinct species in reports 1
Distinct breeds in reports 18
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Florfenicol + Terbinafine + Mometasone Furoate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 21 adverse event reports referencing Florfenicol + Terbinafine + Mometasone Furoate, including 2 reports in which the animal died — a 950.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Florfenicol + Terbinafine + Mometasone Furoate. Reported administration routes include Auricular (Otic), Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Florfenicol + Terbinafine + Mometasone Furoate reports are Dog (21 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (3), Spaniel - Cocker American (2), Shiba Inu (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Florfenicol + Terbinafine + Mometasone Furoate are Vomiting (7), Decreased urine concentration (2), Death (2), Lack of efficacy - NOS (2). Of the 21 reports with a coded outcome, Recovered/Normal is the leading category at 33.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Florfenicol + Terbinafine + Mometasone Furoate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial